Cystic Fibrosis News Today Daily Digest

Cystic Fibrosis Weekly Update Contents: Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data Sep 14, 2020 07:00 am | Marisa Wexler MS Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is safe for use in children with cystic fibrosis (CF) as young as age 6, data from a global Phase 3 clinical trial show. Based on these results, Vertex Pharmaceuticals, which markets Trikafta, will seek an expansion of the medication’s current U.S. approval, which covers patients ages 12 and older. Vertex […] The post Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data appeared first on Cystic Fibrosis News Today. Read More Recent News How to Keep Your Growth Game Strong Activities Underway for Newborn Screening Awareness Month Aridis, FDA Agree to Simplify AR-501 Trial Design Based on Positive Safety Data Savara Closing Trial of Molgradex in Treating NTM Lung Infections in CF Patients Listening to Both Sides of the Mask Debate